Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

InnoCare Pharma Limited (HKG: 9969; SHA: 688428) announced that it has entered into a strategic research, development, and licensing agreement with Eli Lilly and Company (NYSE: LLY) to develop innovative…

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies

CompanyDrug

BriSTAR Immunotech’s LILRB4-Targeted Cell Therapy YTS104 Gets Tacit Approval for Clinical Trial in China

CompanyDrug

Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment

CompanyDrug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

CompanyDrug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

CompanyDrug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

CompanyDrug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

CompanyDrug

Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent

Show More